← Leaderboards
Leslie Lupien
Dana-Farber Cancer Inst
$205,268
Attributed
$205,268
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $71.8K · FY2021–23$100K$75K$50K$25K$0
'21
'22
'23
Funding mix
By agency
NIH$205,268 · 1
By mechanism
F32$205,268 · 1
Top collaborators
No co-investigators on record.
Most similar at Dana-Farber Cancer Inst
Same institution · by research overlap
- Kornelia Polyak$28,582,691
- Geoffrey I Shapiro$18,639,470
- Pratiti Bandopadhayay$2,988,759
- Jennifer L. Guerriero$2,031,971
- A. Heather Eliassen$24,939,674
Others in their field
Other Emerging Leaders on “Acetyl Coenzyme A”
- Srikanth Singamsetty · Phoenix Nest, Inc.$5,047,122
- Prashant Mishra · Ut Southwestern Medical Center$2,999,512
- Jae Mo Park · Ut Southwestern Medical Center$2,739,634
- Zachary T Schug · Wistar Institute$2,679,000
- Wenbo Li · University Of Texas Hlth Sci Ctr Houston$2,244,810
- Michelle Van Name · Yale University$2,148,055
Research focus
Acetyl Coenzyme ADifferential ExpressionBinding ProteinsBinding SitesBromodomainAnticholesteremic AgentsCancer CellCell Cycle ProgressionCellsCharacteristicsChildChildhood Brain NeoplasmCholesterolCholesterol BiosynthesisCholesterol HomeostasisChromatin ImmunoprecipitationClinical TrialsCombined Modality TherapyComplexCrispr/Cas TechnologyCytochromesDependenceDesaturaseDrug Resistance
Grant awards (3)
Lipid metabolism as a therapeutic vulnerability in BET inhibitor-resistant medulloblastoma$71,792
F32 · FY2023 · CA · contact PI
Lipid metabolism as a therapeutic vulnerability in BET inhibitor-resistant medulloblastoma$67,482
F32 · FY2022 · CA · contact PI
Lipid metabolism as a therapeutic vulnerability in BET inhibitor-resistant medulloblastoma$65,994
F32 · FY2021 · CA · contact PI